SCHEMBL3003579

SCHEMBL3003579

COc1ccc(OC)c(Cc2csc(N3CCN(S(=O)(=O)c4ccc(Cl)cc4Cl)CC3)n2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
LMNA P02545 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
USP2 O75604 2/20 0.45
HTT P42858 1/20 0.45
KMT2A Q03164 3/20 0.44
MAPT P10636 3/20 0.44
RECQL P46063 2/20 0.44
MEN1 O00255 1/20 0.44
TSHR P16473 1/20 0.43
KDM4E B2RXH2 2/20 0.43
POLB P06746 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TP53 P04637 2/20 0.41
ACLY P53396 1/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3019561 0.94 ALDH1A1 (0.51) ALDH1A1LMNAL3MBTL1USP2HTT
SCHEMBL3020101 0.93 ALDH1A1 (0.43) ALDH1A1LMNAL3MBTL1USP2HTT
SCHEMBL3005635 0.93 KMT2A (0.46) ALDH1A1LMNAL3MBTL1USP2HTT
SCHEMBL3009391 0.92 ALDH1A1 (0.43) ALDH1A1LMNAL3MBTL1USP2HTT
SCHEMBL3016747 0.92 MAPT (0.47) ALDH1A1LMNAL3MBTL1USP2HTT
SCHEMBL3013779 0.91 ALDH1A1 (0.49) ALDH1A1LMNAL3MBTL1USP2HTT
SCHEMBL3017745 0.91 L3MBTL1 (0.48) ALDH1A1LMNAL3MBTL1USP2HTT
SCHEMBL3012014 0.90 ALDH1A1 (0.56) ALDH1A1LMNAL3MBTL1USP2HTT
SCHEMBL3014589 0.90 ALDH1A1 (0.47) ALDH1A1LMNAL3MBTL1USP2HTT
SCHEMBL3012765 0.90 ALDH1A1 (0.52) ALDH1A1LMNAL3MBTL1USP2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885LMNA 80/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.